PanTher Therapeutics Company Profile - aVenture Research
PanTher Therapeutics
PanTher Therapeutics, a clinical-stage oncology company, develops high-dose, long-lasting, localized cancer treatments administered continuously and exclusively at the tumor site.
PanTher Therapeutics is a clinical-stage oncology company developing high-dose, long-lasting, localized treatments for cancer. Its foundational Sagittari platform technology was invented at the Massachusetts Institute of Technology. It creates drug products optimized for dose and duration and engineered for integration into existing interventional oncology procedures, including its lead product candidate PTM-101, a treatment for pancreatic cancer.
Its drug product is designed to continuously deliver drug for weeks or months at a desired dose level without unwanted dose-limiting side effects. Available chemotherapeutic agents' effectiveness is often limited by systemic dose-limiting toxicities. Its lead program is in a clinical study in patients with pancreatic ductal adenocarcinoma.